Cormorant Asset Management YMAB Position
ExitedCormorant Asset Management exited their position in Y-mAbs Therapeutics Inc. (YMAB) in Q1 2025, after holding the stock for 4 quarters.
The position was first reported in Q2 2024 and has been tracked across 4 quarterly 13F filings.
About Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
Full company profile →Cormorant Asset Management YMAB Position History
Frequently Asked Questions
Does Cormorant Asset Management own YMAB?
No. Cormorant Asset Management exited their position in Y-mAbs Therapeutics Inc. (YMAB) in Q1 2025. They previously held the stock for 4 quarters.
How many hedge funds own YMAB?
Based on the 20 specialist biotech hedge funds tracked by BiotechEdge, no tracked fund currently holds an active position in YMAB.
When did Cormorant Asset Management first buy YMAB?
Cormorant Asset Management's position in YMAB was first reported in Q2 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Cormorant Asset Management's YMAB position increasing or decreasing?
Cormorant Asset Management completely exited their YMAB position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
YMABCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Cormorant Asset ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →